Eric W. Linsley
Partner @ Pappas Ventures
Durham, United States
Eric W. Linsley is a Series A investor at Pappas Ventures in Durham focused on Biotechnology and Therapeutics. Eric W. Linsley - Partner @ Pappas Ventures
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Eric W. Linsley invests in
Stages Eric W. Linsley invests in
Countries Eric W. Linsley invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Therapeutics 3 (43%)
- Health Care 2 (29%)
- Biopharma 1 (14%)
- Medical Device 1 (14%)
Stage
- Series A 2 (29%)
- Series B 1 (14%)
- Series C 1 (14%)
- Series D 1 (14%)
Country
- United States 3 (43%)
- Canada 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cereius is a pre-clinical stage company developing novel approaches to treating solid tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targetingagents. | $6.5M / Series A / Jul 25, 2018 | ||
| Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M / Series B / Jun 15, 2015 | ||
| Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $5M / Series C / Jul 13, 2010 | ||
| Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $20M / Series C / Jan 19, 2010 | ||
| BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovativeapproach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery. | $27M / Series D / Aug 24, 2009 | ||
| Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $13M / Series A | ||
| See all 7 investments → | |||
Co-Investors
About Pappas Ventures
Pappas Ventures provides investment in the life sciences sector.
Pappas Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Artthur M. Pappas
Founder, CEO & Managing General Partner
|
|||
|
Eric W. Linsley
Partner
|
|||
Ford Worthy
Partner
|
|||
Franz Humer
Venture partner and Senior editor
|
|||
Mike Grey
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eric W. Linsley invest in?
Eric W. Linsley invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eric W. Linsley?
Public channels for Eric W. Linsley include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eric W. Linsley last invest?
The most recent investment recorded for Eric W. Linsley closed in Jul 2018. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
